Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein

Isabella Russo, Paola Del Mese, Gabriella Doronzo, Alessandro De Salve, Mariantonietta Secchi, Mariella Trovati, Giovanni Anfossi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Impairment of platelet response to antiaggregatory agents is seen in individuals with central obesity and may play a role in the increased cardiovascular risk associated with obesity. In this study we evaluated whether this impairment involves the antiaggregatory pathways regulated by cAMP and cGMP. Methods: We obtained platelet-rich plasma from 12 obese individuals and 12 controls. We investigated the effects of the cyclic nucleotide analogs 8-pCPT-cAMP (10-500 μmol/L) and 8-pCPT-cGMP (10-500 μmol/L) on ADP-induced platelet aggregation as assessed by decreased light scattering. We assessed the activation of cAMP- and cGMP-dependent protein kinases by measuring phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) at Ser157 and Ser239. Results: The antiaggregatory effect of both cyclic nucleotide analogs was impaired in obese individuals compared to controls, with mean (SE) half-maximal inhibitory concentrations (IC50) (after 20-min incubation) of 123 (33) μmol/L vs 5 (1) μmol/L, respectively, for 8-pCPT-cAMP (P 50. In obese individuals, VASP phosphorylation at Ser157 and Ser239 in response to cyclic nucleotides was significantly lower than in controls. Conclusions: In central obesity the reduced ability of cyclic nucleotides to inhibit platelet aggregation is associated with reduced activation of their specific kinases. Because cyclic nucleotides help regulate platelet antiaggregation, alteration of this ability is consistent with platelet hyperactivity in obesity.

Original languageEnglish
Pages (from-to)1053-1060
Number of pages8
JournalClinical Chemistry
Volume53
Issue number6
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Phosphorylation
Abdominal Obesity
Cyclic Nucleotides
Platelets
Blood Platelets
Platelet Aggregation
Obesity
Agglomeration
Cyclic GMP-Dependent Protein Kinases
Chemical activation
Platelet-Rich Plasma
Cyclic AMP-Dependent Protein Kinases
Adenosine Diphosphate
Inhibitory Concentration 50
Phosphotransferases
Light scattering
vasodilator-stimulated phosphoprotein
Light
Plasmas

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. / Russo, Isabella; Del Mese, Paola; Doronzo, Gabriella; De Salve, Alessandro; Secchi, Mariantonietta; Trovati, Mariella; Anfossi, Giovanni.

In: Clinical Chemistry, Vol. 53, No. 6, 06.2007, p. 1053-1060.

Research output: Contribution to journalArticle

Russo, Isabella ; Del Mese, Paola ; Doronzo, Gabriella ; De Salve, Alessandro ; Secchi, Mariantonietta ; Trovati, Mariella ; Anfossi, Giovanni. / Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. In: Clinical Chemistry. 2007 ; Vol. 53, No. 6. pp. 1053-1060.
@article{a9ccad5a792b4027b1ca82324861d27a,
title = "Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein",
abstract = "Background: Impairment of platelet response to antiaggregatory agents is seen in individuals with central obesity and may play a role in the increased cardiovascular risk associated with obesity. In this study we evaluated whether this impairment involves the antiaggregatory pathways regulated by cAMP and cGMP. Methods: We obtained platelet-rich plasma from 12 obese individuals and 12 controls. We investigated the effects of the cyclic nucleotide analogs 8-pCPT-cAMP (10-500 μmol/L) and 8-pCPT-cGMP (10-500 μmol/L) on ADP-induced platelet aggregation as assessed by decreased light scattering. We assessed the activation of cAMP- and cGMP-dependent protein kinases by measuring phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) at Ser157 and Ser239. Results: The antiaggregatory effect of both cyclic nucleotide analogs was impaired in obese individuals compared to controls, with mean (SE) half-maximal inhibitory concentrations (IC50) (after 20-min incubation) of 123 (33) μmol/L vs 5 (1) μmol/L, respectively, for 8-pCPT-cAMP (P 50. In obese individuals, VASP phosphorylation at Ser157 and Ser239 in response to cyclic nucleotides was significantly lower than in controls. Conclusions: In central obesity the reduced ability of cyclic nucleotides to inhibit platelet aggregation is associated with reduced activation of their specific kinases. Because cyclic nucleotides help regulate platelet antiaggregation, alteration of this ability is consistent with platelet hyperactivity in obesity.",
author = "Isabella Russo and {Del Mese}, Paola and Gabriella Doronzo and {De Salve}, Alessandro and Mariantonietta Secchi and Mariella Trovati and Giovanni Anfossi",
year = "2007",
month = "6",
doi = "10.1373/clinchem.2006.076208",
language = "English",
volume = "53",
pages = "1053--1060",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "6",

}

TY - JOUR

T1 - Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein

AU - Russo, Isabella

AU - Del Mese, Paola

AU - Doronzo, Gabriella

AU - De Salve, Alessandro

AU - Secchi, Mariantonietta

AU - Trovati, Mariella

AU - Anfossi, Giovanni

PY - 2007/6

Y1 - 2007/6

N2 - Background: Impairment of platelet response to antiaggregatory agents is seen in individuals with central obesity and may play a role in the increased cardiovascular risk associated with obesity. In this study we evaluated whether this impairment involves the antiaggregatory pathways regulated by cAMP and cGMP. Methods: We obtained platelet-rich plasma from 12 obese individuals and 12 controls. We investigated the effects of the cyclic nucleotide analogs 8-pCPT-cAMP (10-500 μmol/L) and 8-pCPT-cGMP (10-500 μmol/L) on ADP-induced platelet aggregation as assessed by decreased light scattering. We assessed the activation of cAMP- and cGMP-dependent protein kinases by measuring phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) at Ser157 and Ser239. Results: The antiaggregatory effect of both cyclic nucleotide analogs was impaired in obese individuals compared to controls, with mean (SE) half-maximal inhibitory concentrations (IC50) (after 20-min incubation) of 123 (33) μmol/L vs 5 (1) μmol/L, respectively, for 8-pCPT-cAMP (P 50. In obese individuals, VASP phosphorylation at Ser157 and Ser239 in response to cyclic nucleotides was significantly lower than in controls. Conclusions: In central obesity the reduced ability of cyclic nucleotides to inhibit platelet aggregation is associated with reduced activation of their specific kinases. Because cyclic nucleotides help regulate platelet antiaggregation, alteration of this ability is consistent with platelet hyperactivity in obesity.

AB - Background: Impairment of platelet response to antiaggregatory agents is seen in individuals with central obesity and may play a role in the increased cardiovascular risk associated with obesity. In this study we evaluated whether this impairment involves the antiaggregatory pathways regulated by cAMP and cGMP. Methods: We obtained platelet-rich plasma from 12 obese individuals and 12 controls. We investigated the effects of the cyclic nucleotide analogs 8-pCPT-cAMP (10-500 μmol/L) and 8-pCPT-cGMP (10-500 μmol/L) on ADP-induced platelet aggregation as assessed by decreased light scattering. We assessed the activation of cAMP- and cGMP-dependent protein kinases by measuring phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) at Ser157 and Ser239. Results: The antiaggregatory effect of both cyclic nucleotide analogs was impaired in obese individuals compared to controls, with mean (SE) half-maximal inhibitory concentrations (IC50) (after 20-min incubation) of 123 (33) μmol/L vs 5 (1) μmol/L, respectively, for 8-pCPT-cAMP (P 50. In obese individuals, VASP phosphorylation at Ser157 and Ser239 in response to cyclic nucleotides was significantly lower than in controls. Conclusions: In central obesity the reduced ability of cyclic nucleotides to inhibit platelet aggregation is associated with reduced activation of their specific kinases. Because cyclic nucleotides help regulate platelet antiaggregation, alteration of this ability is consistent with platelet hyperactivity in obesity.

UR - http://www.scopus.com/inward/record.url?scp=34249879295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249879295&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2006.076208

DO - 10.1373/clinchem.2006.076208

M3 - Article

C2 - 17463178

AN - SCOPUS:34249879295

VL - 53

SP - 1053

EP - 1060

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 6

ER -